Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company’s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals. 

Therapeutics

Life Sciences

Health Care

Biotechnology

Radionetics Oncology

Paul Grayson

Linda McLaughlin

Janine Case

Kristrun Thordis Stardal

Brett Ewald

Yunfei Zhu

Istvan Molnar

The Research and Development team at Radionetics Oncology is dedicated to advancing the company's innovative radiotherapeutic pipeline. Comprising experts in biology and chemistry, the team focuses on discovering and optimizing novel drug candidates that selectively target cancer-associated peptide receptors using their proprietary nonpeptide technology. They collaborate with industry partners to overcome challenges in drug development and ensure the successful translation of scientific discoveries into effective therapies for a wide range of oncology indications.

Research and Development

Leadership Team

Human Resources and Administration

Research and Development

About

Team members

Other teams at Radionetics Oncology

Leadership Team

Human Resources and Administration